2004 WHO Classification of the Renal Tumors of the Adults, European Urology, vol.49, issue.5, pp.798-805, 2006. ,
DOI : 10.1016/j.eururo.2005.11.035
What Does the Urologist Expect from the Pathologist (and What Can the Pathologists Give) in Reporting on Adult Kidney Tumour Specimens?, European Urology, vol.51, issue.5, pp.1194-201, 2007. ,
DOI : 10.1016/j.eururo.2006.11.024
Tumour suppression by the human von Hippel-Lindau gene product, Nature Medicine, vol.162, issue.8, pp.822-828, 1995. ,
DOI : 10.1038/nm0895-822
Somatic mutations of the von Hippel ??? Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma, Human Molecular Genetics, vol.3, issue.12, pp.2169-73, 1994. ,
DOI : 10.1093/hmg/3.12.2169
The von Hippel???Lindau Tumor Suppressor Gene, Experimental Cell Research, vol.264, issue.1, pp.117-142, 2001. ,
DOI : 10.1006/excr.2000.5139
The biology of VEGF and its receptors, Nature Medicine, vol.9, issue.6, pp.669-76, 2003. ,
DOI : 10.1038/nm0603-669
Molecular regulation of vessel maturation, Nature Medicine, vol.9, issue.6, pp.685-93, 2003. ,
DOI : 10.1038/nm0603-685
The phosphatidylinositol 3-Kinase???AKT pathway in human cancer, Nature Reviews Cancer, vol.2, issue.7, pp.489-501, 2002. ,
DOI : 10.1038/nrc839
mTOR and cancer: insights into a complex relationship, Nature Reviews Cancer, vol.10, issue.9, pp.729-763, 2006. ,
DOI : 10.1038/nrc1974
Altered expression of transforming growth factor-??: An early event in renal cell carcinoma development, Molecular Carcinogenesis, vol.35, issue.3, pp.213-222, 1997. ,
DOI : 10.1002/(SICI)1098-2744(199707)19:3<213::AID-MC9>3.0.CO;2-E
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas, Nature Genetics, vol.4, issue.1, pp.68-73, 1997. ,
DOI : 10.1038/ng1295-402
Invasive growth: a MET-driven genetic programme for cancer and stem cells, Nature Reviews Cancer, vol.16, issue.8, pp.637-682, 2006. ,
DOI : 10.1038/nrc1912
Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer, Nature Genetics, vol.30, issue.4, pp.406-416, 2002. ,
DOI : 10.1038/ng849
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.2, pp.125-159, 2007. ,
DOI : 10.1056/NEJMoa060655
Growing opportunities for adjuvant therapy of renal cell carcinoma: targeted drugs and vaccines, Expert Opinion on Pharmacotherapy, vol.24, issue.17, pp.2979-90, 2007. ,
DOI : 10.1200/JCO.2005.10.017
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.22, pp.2271-81, 2007. ,
DOI : 10.1056/NEJMoa066838
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, The Lancet, vol.372, issue.9637, pp.449-56, 2008. ,
DOI : 10.1016/S0140-6736(08)61039-9
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist, Proceedings of the National Academy of Sciences, vol.101, issue.48, pp.16768-73, 2004. ,
DOI : 10.1073/pnas.0407617101
Modes of resistance to anti-angiogenic therapy, Nature Reviews Cancer, vol.25, issue.8, pp.592-603, 2008. ,
DOI : 10.1038/nrc2442
Opportunities and Obstacles to Combination Targeted Therapy in Renal Cell Cancer, Clinical Cancer Research, vol.13, issue.2, pp.764-69, 2007. ,
DOI : 10.1158/1078-0432.CCR-06-1975
Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell renal cell carcinoma, Urology, vol.65, issue.6, pp.1090-1095, 2005. ,
DOI : 10.1016/j.urology.2004.12.040
von Hippel-Lindau Gene Status and Response to Vascular Endothelial Growth Factor Targeted Therapy for Metastatic Clear Cell Renal Cell Carcinoma, The Journal of Urology, vol.180, issue.3, pp.860-865, 2008. ,
DOI : 10.1016/j.juro.2008.05.015
Hypoxia-Inducible Factor 1?? in Clear Cell Renal Cell Carcinoma, Clinical Cancer Research, vol.13, issue.24, pp.7388-93, 2007. ,
DOI : 10.1158/1078-0432.CCR-07-0411
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy, Clin Cancer Res, vol.9, pp.802-813, 2003. ,
Hypoxia-inducible factor (HIF) 1?? and 2?? levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC), Journal of Clinical Oncology, vol.26, issue.15_suppl, p.5008, 2008. ,
DOI : 10.1200/jco.2008.26.15_suppl.5008
Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases, Human Pathology, vol.38, issue.10, pp.1489-95, 2007. ,
DOI : 10.1016/j.humpath.2007.02.014
Prognostic relevance of the mTOR pathway in renal cell carcinoma, Cancer, vol.9, issue.11, pp.2257-67, 2007. ,
DOI : 10.1002/cncr.22677
Potential Histologic and Molecular Predictors of Response to Temsirolimus in Patients with Advanced Renal Cell Carcinoma, Clinical Genitourinary Cancer, vol.5, issue.6, pp.379-85, 2007. ,
DOI : 10.3816/CGC.2007.n.020